Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Same Exact trading pattern as the one happened early last week before taking off to 0.30+
When Was Alcoholism Discovered
April 13, 2017 by A2a Market Research Staff
C O N T E N T S:
KEY TOPICS
•A 2015 study, funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), discovered a gene variant that affects the release of a specific brain protein that may increase the risks for alcohol use disorder (AUD).(More…)
•New Drug for Temporal Lobe Epilepsy Discovered A recent study has discovered a new class of drugs.(More…)
•The only consistent treatment for alcoholism and addiction was discovered in 1935 when two alcoholics began to have conversations about their unquenchable desire to drink.(More…)
•A 2001 study of how people were doing after alcoholism treatment discovered that 60.5 % of sufferers who did not have another psychological well being points in addition to addiction managed to stay sober.(More…)
•The first group of recovering addicts who just began treatment in a rehab facility was asked: “If scientists discovered a cure-all vaccine for drug and alcohol addiction, would you agree to take the vaccine?”(More…)
•Methamphetamine was originally discovered in 1919 and used as a treatment for issues including depression, narcolepsy, obesity, ADHD, and alcoholism.(More…)
•Years later congress discovered that the drug actually wasn’t all that beneficial, and they went on to categorize it as a Schedule II drug.(More…)
POSSIBLY USEFUL
•Alcohol Consumption in Young People Can Lead to Alcoholism Later in Life Alcoholism Alcoholism is a condition characterized by a distinct physical.(More…)
description: He Drinks Everyday. Is My Husband an Alcoholic?
KEY TOPICS
A 2015 study, funded by the National Institute on Alcohol Abuse and Alcoholism (NIAAA), discovered a gene variant that affects the release of a specific brain protein that may increase the risks for alcohol use disorder (AUD). [1] Building on work first done in mice, scientists have discovered a particular genetic variation that’s more common in alcoholics, while alcoholism is rare in people who carry a different mutation. [2]
New Drug for Temporal Lobe Epilepsy Discovered A recent study has discovered a new class of drugs. [3] New Drug for Measles Discovered Measles Measles is a viral infection that can give rise. [3]
The only consistent treatment for alcoholism and addiction was discovered in 1935 when two alcoholics began to have conversations about their unquenchable desire to drink. [4] There?s hope for treatment, if the disease is discovered soon enough–but drastic changes must be made in a person?s life to ensure that it doesn?t get worse. [5] Scientists discovered that mice carrying the Met68BDNF gene variant responsible for reducing the release of brain-derived neurotrophic factor (BDNF) continued to consume excessive levels of alcohol regardless of its negative consequences. [1] We have also discovered that we can deliver two weeks of drug release in vivo in a very low volume of approximately 0.5 ml. [6] Our primary goal is to achieve a once a month injectable product in a low volume and small needle, along with many other advantages over current products, but what we discovered in the last few weeks of studies may lend itself to another possible product. [6] What is particularly exciting about this round of data is that we have discovered that we may have two different lead formulations that may lead to 2-3 different types of products in the future. [6]
The report also discovered those who make more than $75,000 are more apt to binge drink. [7]
A 2001 study of how people were doing after alcoholism treatment discovered that 60.5 % of sufferers who did not have another psychological well being points in addition to addiction managed to stay sober. [8] Recently, it was discovered that there is actually a link between those who have an addiction to indoor tanning, as well as those who suffer from addictive behaviors like alcoholism. [9] I have also discovered that alcoholism is a machine, which consists of four gears. [10]
The first group of recovering addicts who just began treatment in a rehab facility was asked: “If scientists discovered a cure-all vaccine for drug and alcohol addiction, would you agree to take the vaccine?” To qualify the question, they were told that if they agreed to take the cure, they would never remember any of the past effects from use, nor would they ever again feel the effects of drug or alcohol use. [11] “?When I discovered those social lubricants like alcohol and drugs, they worked instantly.” [12]
The term refers to the brain’s recently discovered ability to change its structure and function, in particular by expanding or strengthening circuits that are used and by shrinking or weakening those that are rarely engaged. [11] To quote from the AA big book again from this chapter; “Much to our relief, we discovered we did not need to consider another’s conception of God. [13] Now it’s been discovered that your family history might be responsible for horrible hangovers. [14]
Methamphetamine was originally discovered in 1919 and used as a treatment for issues including depression, narcolepsy, obesity, ADHD, and alcoholism. [15] In 2005, a study of people with anxiety disorders who had gone by means of rehab for alcohol discovered that they have been “significantly more likely” to relapse than individuals who did not produce other psychological well being points along with addiction. [8] The was a recent study done by Yale School of Public Health, and it discovered that there was a connection between tanning dependence and alcohol dependence. [9]
They discovered that the number of women who binge drink rose roughly 4 percent per year, while the proportion of binge-drinking men remained consistent. (Binge drinking is defined as 4 drinks within a few hours for women, and 5 for men.) [16] In 2012, Science Direct discovered “a statistically significant association between peer-nominated popularity and the probability of alcohol consumption” They even went so far as to suggest a direct relationship between making more friends and drinking more. [17]
One factor they discovered that could potentially play a role, is the fact that there is a brain phenomenon connected with certain types of tanning. [9] Five major alterations to normal brain behavior were discovered. [17]
He, however, said that he had also discovered that in spite of their innate potential in sports, so many of the youth shy away from sports and loiter. [18] Logan told the News Agency of Nigeria (NAN) in Jos that he had discovered that Plateau youths were exceptionally good in various sports. [18]
Years later congress discovered that the drug actually wasn’t all that beneficial, and they went on to categorize it as a Schedule II drug. [15] There are no definitive causes of ASD but it has been discovered that there are several factors that can make a child more likely to have the disorder. [19]
POSSIBLY USEFUL
Alcohol Consumption in Young People Can Lead to Alcoholism Later in Life Alcoholism Alcoholism is a condition characterized by a distinct physical. [3] That’s the nice thing about alcoholism: if you don’t drink you don’t have a problem with it. (But if you pick up one drink, life turns into a horror show quickly.) [20]
The problem with alcoholism is that it?s characterized by a person lacking control of his or her alcohol intake–even when their physical and mental health is deteriorating. [5] ANAHEIM, CA / ACCESSWIRE / March 21, 2017 / BioCorRx Inc. (OTC PINK: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced positive preliminary data from preclinical studies evaluating BICX101, a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. [6] [xyz-ihs snippet=”Amazon-Affiliate-Native-Ads”] The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. [6]
Either condition can be fatal, and treatment options are limited” ( National Institute on Alcohol Abuse and Alcoholism ). [5] Alcohol is to blame for about 60 percent of fatal burn injuries and drownings, and 40 percent of fatal falls and car accidents, according to the National Institute on Alcohol Abuse and Alcoholism (NIAAA). [7]
First and foremost, alcoholic beverages must be completely cut out of the diet, which can prove to be difficult for a person suffering from a disease like alcoholism. [5] Alcoholism has been found to run in families, with children of alcoholics four times more likely than the general population to develop alcohol problems. [2] Alcoholism Alcohol problems vary in severity from mild to life threatening and affect the individual, the person’s family, and society in numerous adverse ways. [21]
Alcoholism can cause liver damage, lower mental or physical function, hypertension and cancer of various types. [1] Avoid underage drinking, as it’s been shown to increase the risk of alcoholism. [2]
Alcoholic hepatitis is brought on by frequent excessive alcohol consumption, alcohol use disorders and acute alcoholism. [5] Symptoms of acute alcoholic hepatitis are similar to acute alcoholism and–though “in multiple studies, the strongest factor predictive of short-term mortality was hepatic encephalopathy” ( Medscape ). [5]
By definition, acute alcoholism is–intoxication resulting from excessive consumption of alcoholic beverages. [5]
The closest the book Alcoholics Anonymous comes to a definition of alcoholism appears on p. 44, at the conclusion of the first paragraph of the “We Agnostics” chapter, where we are told that alcoholism “is an illness which only a spiritual experience will conquer.” [11] According to Olivier Ameisen, a noted French cardiologist who wrote a book detailing his experience using baclofen to overcome his alcoholism, the drug creates an almost complete indifference to alcohol, The Guardian reported. [22] Due to these positive results, Ethypharm, the company who developed baclofen, announced that they will submit an application to the French government to allow the commercialization of the drug for the treatment of alcoholism in France. [22] This is not the first time that baclofen has been in the news; in 2014 French health authorities gave provisional approval for it to be used as an alcoholism treatment. [22]
With someone of Affleck?s high-profile status stepping forward to shed light on an issue that affects countless American families, we celebrate his openness and reflect upon lowering the stigma surrounding alcoholism and addiction treatment. [23] When we accept the unproven view that addiction and alcoholism are brain diseases, then it will lead us down a long, painful, costly, and pointless road of cycling in and out of ineffective treatment programs and 12 step meetings. [11] “There are zillions of people who say that alcoholism is a disease, but not many of them believe it.” [11] It is common knowledge that people with a family history of alcoholism are at greater risk of having drinking problems themselves. [14]
The first study revealed that those with alcoholism in their families recalled having more frequent post-drinking symptoms. [14] “We have never called alcoholism a disease because, technically speaking, it is not a disease.” [11] In a 2012 Barbara Walters interview, Affleck revealed that his father had battled alcoholism throughout his life. [23] Elinor Landess, director of the Campus and Community Coalition, used this analogy to describe the mindset that surrounds alcoholism in American culture. [12]
The team believes that not only could the work lead to better targeting of existing drugs, it could also help to develop new drug treatments for alcoholism. [24] The team believes the findings could help to improve existing drug treatments for alcoholism by targeting them to those who are most likely to benefit, and even lead to the development of more effective treatments. [24]
A Dutch study from 2016 determined that baclofen worked no better than counseling and suggested hesitation with its use for alcoholism treatment. [22] Ben Affleck?s name splashed across headlines worldwide yesterday as he made a candid Facebook post to confirm that he recently completed treatment for alcoholism. [23] Moving away from the psychiatric disorders, don?t you want to know if you?re an alcoholic? The National Council on Alcoholism and Drug Dependence (NCADD) made a nifty questionnaire to help you take your first step toward a definitive answer. [17] A study conducted in 2007 by the National Council on Alcoholism reported that people attending 12-step treatment programs had a 49.5% abstinence rate after a single year. [17] Study author Rosalind Breslow, an epidemiologist at the U.S. National Institute on Alcohol Abuse and Alcoholism, told CBS News the increased drinking among both genders may be a carry-over from their youth. [25] This is troubling for a few different reasons, study author Rosalind Breslow, an epidemiologist at the U.S. National Institute on Alcohol Abuse and Alcoholism, told HealthDay. [16]
That?s just one statistic from one study so please don?t ignore that alcoholism is everywhere. [17]
What about sanctioned alcoholism that has, in this day and age, come in the form of bar crawls, frat parties, fundraisers, drinking games, open bars at weddings and any other venue or event that will allow alcohol? Are we forgetting that alcoholism is a disease? Alcoholism, as the late Mitch Hedberg said, is the only disease you can be yelled at for having. [17] The brain cannot function without alcohol, and we call this alcoholism. [17]
“Evidence for a causal relationship,” Comprehensive Psychiatry noted in 1998, “is not unidirectional as alcoholism is often observed as a primary disorder, and the presence of problem drinking itself may generate severe anxiety or depressive syndromes.” [8] Stop drinking without AA: How to overcome alcoholism, and restore your life, without a single AA meeting. [10] Most of the tricks to quit drinking, which are available today, encompass behavioral modification techniques in relation to the effects of alcoholism. [10] If you use these tricks or tips, essentially, you are managing the effects of alcoholism. [10] Alcoholism has many faces and we can?t ignore the health effects of alcoholism being more prominent in individuals of low socioeconomic status. [17] Think of it like cigarettes – do you have to stop what you?re doing to have a drink? Is there an urge that is nagging you so much you can?t get through the day without a drink? Alcoholism is an addiction and cravings go hand and hand with addictions. [17] Clearly, getting wholesome whereas struggling the comorbidity of alcoholism and nervousness disorders is an enormous hurdle, and we’re not solely positive find out how to repair it. [8] These symptoms develop after the acute withdrawal period, and can last for a couple of weeks all the way up to a year depending on the severity of prior alcoholism. [17] None of these participants, however, had diagnosed alcoholism. (This is a very important factor, and will be brought up later on). [17] The Director of Sports, Plateau State Sports Council, Mr. Dapar Logan, on Friday advised youths in the state to shun alcoholism and embrace sports as a way to better their lives. [18] The most common psychiatric disorders that co-occur with alcoholism are depressive disorders and bipolar disorder, which are both under the mood disorder umbrella. [17]
The National Institute on Alcohol, Abuse and Alcoholism provides some frightening annual statistics regarding drinking and college students ages 18 to 24. [26] According to the National Institute on Alcohol Abuse and Alcoholism, people with a family history of alcohol abuse are about four times as likely to develop a problem with alcohol themselves, but this can’t simply be summed up to an “alcoholism gene.” [27] “Given the larger number of Americans we are going to have (as the population ages), that’s going to increase the need for more public health programming,” said study author Rosalind Breslow, an epidemiologist at the U.S. National Institute on Alcohol Abuse and Alcoholism. [28]
A new study suggests that the ability to vividly remember a hangover, sometimes even months after you’ve made a full recovery, isn’t linked to how much you drink, but rather who is in your family A family history of alcoholism may influence more than your ability to remember a hangover; it could also influence your likeliness to develop the condition as well. [27]
During this month, people are especially urged to participate in community outreach activities to disseminate information about alcohol, alcoholism and recovery. [19] A lot of alcoholics say the difference between someone who has alcoholism and someone who doesn’t is that most people have this thing inside them that tells them they should stop drinking. [27] Many people are unaware that alcoholism is a chronic progressive disease, genetically predisposed and can be fatal if left untreated. [19]
It is difficult for the bride of Christ to prepare herself for her coming Bridegroom when she regularly has to deal with alcoholism, drug abuse, pornography obsessions, etc. Our forward momentum in advancing God?s kingdom is slowed because so many can?t break the chains of addiction. [29] Culturally-sensitive treatment is provided by a dedicated and caring staff that consists of physicians, physicians? assistants, specially trained nurses, credentialed alcoholism and substance abuse counselors, creative arts therapists, social workers, and psychiatric consultants. [19]
March 24 The problem of dying whites can’t only be blamed on rising rates of drug overdoses, suicides and chronic alcoholism, they say. [27] It’s important to understand that binge drinking and alcoholism are not the same. [27]
Not long after that, I admitted myself to a treatment program for alcoholism. [30]
U.S. Prisons Relying on Naltrexone to Treat Inmates Addicted to Opioids
Komfie Manalo
By Komfie Manalo
Apr 12, 2017
More U.S. prisons are relying on naltrexone as an effective method in treating inmates with opioid addiction. Jail and prison systems in 28 states across the nation are using naltrexone under the brand name Vivitrol, for their anti-drug addiction program.
A study published in the New England Journal of Medicine has found that most prisons rely on Vivitrol, an extended release naltrexone injected monthly, to reduce opioid and alcohol cravings. Inmates who have opioid addiction are 12 times more likely to overdose in the first two weeks upon their release if their addiction is left untreated.
"Abstinence alone does not cure addiction; people need treatment," said Dr. Warren Ferguson, director of the Health and Criminal Justice Program at the University of Massachusetts Medical School. He commented on the choice of Vivitrol as treatment for opioid addict inmates, "The other thing it does is prevent anybody who uses narcotics to actually get high, or significantly reduces the high. Most importantly, it will prevent overdose and death."
In February this year, the UMass Medical School partnered with departments of corrections in Connecticut and Rhode Island, as well as the sheriff offices in Barnstable and Middlesex Counties in Massachusetts to study the effects of medication treatment of opioid addiction amongst inmates.
Traditional Medications Methadone or Suboxone Pose Challenges
Some U.S. prisons have been using traditional medications like methadone or Suboxone, as a first-line treatment for opioid abuse that is taken daily. However, while several studies have found that Suboxone and methadone are showing some promise, the treatment itself poses some challenges because both drugs are narcotics and can be abused and taken recreationally.
Suboxone overdose is also being blamed for some deaths. The drug is manufactured by Reckitt Benckiser.
In the case of Vivitrol, the New England Journal of Medicine study is recommending a sustained treatment using the drug as the effects of naltrexone tend to decline when treatment is stopped.
Brady Granier, President, CEO and Director of BioCorRx, Inc. (OTCQB:BICX), an Anaheim, California company developing sustained release naltrexone products commented "naltrexone in any sustained release for can be of great benefit as long as the individual can stay on it for several months or even years in some cases. Suboxone certainly has its utility in some cases as each person's situation is different, but I do think that it can often be used prematurely. It's time for the treatment model to change by putting sustained release naltrexone in the front line when it comes to medication-assisted treatment of opioid use disorder. The argument might be that it's too difficult to get someone detoxed in order to get them on naltrexone, but that's changing. There are many new detox protocols and tools, such as The Bridge device, that can now make the detox period quicker and much less severe. Together, products like this and sustained release naltrexone can be the future standard of treatment."
Naltrexone Shows High Success Rate
Data from the National Center on Addiction and Substance Abuse said that up to 65 percent of inmates across the U.S. are addicted to drugs and alcohol, but only 11 percent receive treatment during incarceration. The collaboration between the private sector and prison management officials is hoped to address the current opioid addiction and make recommendations for improvements, and implementing proven practices to create a model.
The Barnstable County Correctional Facility, the first adult detention facility in Massachusetts to launch a Vivitrol program, has shown promising results in reducing recidivism. Barnstable County Sheriff Jim Cummings reported that 82 percent of the 178 inmates given an injection of the opioid blocker in 2016 have not been incarcerated again. "We are delighted to have been chosen by the prestigious UMass Medical School in Worcester as a partner," Cummings said. "We look forward to where this project will take us. We have much to impart and much still to learn."
The West Virginia Division of Corrections has also incorporated a monthly injection of Vivitrol to its soon-to-be-released inmates and are now showing positive results. Debbie Hissom, Director of Medical Services at the Division of Corrections told The Register Herald that since the program was initiated in July 2015, a total of 47 inmates have participated in it. Hissom said that parole officers of participants who have been paroled have been reporting positive feedbacks about the progress of the participants.
"I think anything we can do is positive," Hissom commented on the program and added, "Of course, it's not a 100 percent success rate. It is voluntary, and lots choose not to enroll. Some start and only get one or two injections."
Sheriff Peter Koutoujian is reporting similar progress at Middlesex County Jail which has also teamed up with UMass. Koutoujian is offers opioid-addicted inmates returning to the community a medication-assisted program that combines enrollment in Medicaid with an injectable form of naltrexone and post-release counseling. But his main focus is to assist inmates in acquiring health insurance.
He said, "Before I became sheriff, we'd hand them a packet so they could sign up for their own Medicaid, a long and complicated process. Upon their release, Middlesex County Jail inmates are assigned with social workers to help in the transition to life on the outside. The social workers will also encourage the drug-addicted inmates will have the means to continue with the treatment at low or no cost at all.
Granier added, "We are encouraged by the increase in the use of Vivitol programs across the country. We hope to one day soon see our own monthly injectable naltrexone product, BICX101, used in these programs as well."
DISCLOSURE: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I have no business relationship with any company whose stock is mentioned in this article.
Rating:
Please Rate:
0.20 is up
GREEN AGAIN :)
looks promising now . PPS climbing
Looks like a green close after all :)
Chasing PPS AGAIN LOL
Just placed a buy order :)
Good move .
U.S. Prisons Relying on Naltrexone to Treat Inmates Addicted to Opioids
More U.S. prisons are relying on naltrexone as an effective method in treating inmates with opioid addiction.
April 10, 2017 | About: BICX +0%
More U.S. prisons are relying on naltrexone as an effective method in treating inmates with opioid addiction. Jail and prison systems in 28 states across the nation are using naltrexone under the brand name Vivitrol, for their anti-drug addiction program.
A study published in the New England Journal of Medicine has found that most prisons rely on Vivitrol, an extended release naltrexone injected monthly, to reduce opioid and alcohol cravings. Inmates who have opioid addiction are 12 times more likely to overdose in the first two weeks upon their release if their addiction is left untreated.
“Abstinence alone does not cure addiction; people need treatment,” said Dr. Warren Ferguson, director of the Health and Criminal Justice Program at the University of Massachusetts Medical School. He commented on the choice of Vivitrol as treatment for opioid addict inmates, “The other thing it does is prevent anybody who uses narcotics to actually get high, or significantly reduces the high. Most importantly, it will prevent overdose and death.”
In February this year, the UMass Medical School partnered with departments of corrections in Connecticut and Rhode Island, as well as the sheriff offices in Barnstable and Middlesex Counties in Massachusetts to study the effects of medication treatment of opioid addiction amongst inmates.
Traditional Medications Methadone or Suboxone Pose Challenges
Some U.S. prisons have been using traditional medications like methadone or Suboxone, as a first-line treatment for opioid abuse that is taken daily. However, while several studies have found that Suboxone and methadone are showing some promise, the treatment itself poses some challenges because both drugs are narcotics and can be abused and taken recreationally.
Suboxone overdose is also being blamed for some deaths. The drug is manufactured by Reckitt Benckiser.
In the case of Vivitrol, the New England Journal of Medicine study is recommending a sustained treatment using the drug as the effects of naltrexone tend to decline when treatment is stopped.
Brady Granier, President, CEO and Director of BioCorRx, Inc. (OTCQB:BICX), an Anaheim, California company developing sustained release naltrexone products commented “naltrexone in any sustained release for can be of great benefit as long as the individual can stay on it for several months or even years in some cases. Suboxone certainly has its utility in some cases as each person’s situation is different, but I do think that it can often be used prematurely. It’s time for the treatment model to change by putting sustained release naltrexone in the front line when it comes to medication-assisted treatment of opioid use disorder. The argument might be that it’s too difficult to get someone detoxed in order to get them on naltrexone, but that’s changing. There are many new detox protocols and tools, such as The Bridge device, that can now make the detox period quicker and much less severe. Together, products like this and sustained release naltrexone can be the future standard of treatment.”
Naltrexone Shows High Success Rate
Data from the National Center on Addiction and Substance Abuse said that up to 65 percent of inmates across the U.S. are addicted to drugs and alcohol, but only 11 percent receive treatment during incarceration. The collaboration between the private sector and prison management officials is hoped to address the current opioid addiction and make recommendations for improvements, and implementing proven practices to create a model.
The Barnstable County Correctional Facility, the first adult detention facility in Massachusetts to launch a Vivitrol program, has shown promising results in reducing recidivism. Barnstable County Sheriff Jim Cummings reported that 82 percent of the 178 inmates given an injection of the opioid blocker in 2016 have not been incarcerated again. “We are delighted to have been chosen by the prestigious UMass Medical School in Worcester as a partner,” Cummings said. “We look forward to where this project will take us. We have much to impart and much still to learn.”
The West Virginia Division of Corrections has also incorporated a monthly injection of Vivitrol to its soon-to-be-released inmates and are now showing positive results. Debbie Hissom, Director of Medical Services at the Division of Corrections told The Register Herald that since the program was initiated in July 2015, a total of 47 inmates have participated in it. Hissom said that parole officers of participants who have been paroled have been reporting positive feedbacks about the progress of the participants.
"I think anything we can do is positive," Hissom commented on the program and added, "Of course, it's not a 100 percent success rate. It is voluntary, and lots choose not to enroll. Some start and only get one or two injections."
Sheriff Peter Koutoujian is reporting similar progress at Middlesex County Jail which has also teamed up with UMass. Koutoujian is offers opioid-addicted inmates returning to the community a medication-assisted program that combines enrollment in Medicaid with an injectable form of naltrexone and post-release counseling. But his main focus is to assist inmates in acquiring health insurance.
He said, "Before I became sheriff, we'd hand them a packet so they could sign up for their own Medicaid, a long and complicated process. Upon their release, Middlesex County Jail inmates are assigned with social workers to help in the transition to life on the outside. The social workers will also encourage the drug-addicted inmates will have the means to continue with the treatment at low or no cost at all.
Granier added, “We are encouraged by the increase in the use of Vivitol programs across the country. We hope to one day soon see our own monthly injectable naltrexone product, BICX101, used in these programs as well.”
DISCLOSURE: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I have no business relationship with any company whose stock is mentioned in this article.
When the FDA thing goes through , we (BICX) will be talking $1+ easy ...
BioCorRx Submits Meeting Request for Pre-IND Meeting with FDA for BICX101
ANAHEIM, CA – (Uptick Newswire – April 10, 2017) – BioCorRx Inc. (OTCQB: BICX) (the “Company”), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that Innovative Science Solutions, LLC (ISS), on behalf of BioCorRx, Inc., has formally requested a pre-IND meeting with the U.S. Food & Drug Administration (FDA) to review the development plan to market BICX101, an injectable, sustained release naltrexone, for the treatment of opioid addiction and alcohol use disorders.
At the pre-IND meeting, BioCorRx plans to seek guidance from the FDA on its proposal to file a New Drug Application (NDA) under Section 505(b)(2) for approval of BICX101, based on the FDA’s previous determination of the safety and effectiveness of naltrexone for the treatment of opioid addiction and alcohol use disorders. Pre-IND meetings are typically scheduled within 60 days of meeting request, but that is up to the FDA and not guaranteed.
Brady Granier, CEO, President, and Director, stated, “The pre-IND meeting request marks an important next step in BioCorRx’s development and approval plan for BICX101. Last week, we announced that multiple formulations under preclinical development were successful in achieving sustained release of naltrexone for 28 days in vivo. Since then, we discovered that one of them had measurable levels at 35 days. We will continue to fine tune these formulas with the goal of achieving maximum efficiency and results while we await the FDA meeting. We are very excited about the potential for BICX101 to be utilized for multiple substance use disorder indications in the future.”
About BioCorRx
BioCorRx Inc. (OTC: BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx® Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The company plans to seek FDA approval for BICX101 and/or its naltrexone implant product(s). For more information on BICX, visit www.BioCorRx.com.
Fasten Your Seat belts !!!!
+ 10k due next week
Hahahah ! You sure do lol
AWESOME WEEK !
AWESOME WEEK!
SELLERS ? Regret ? Anyone ?
rebound happening right now :) BICX is VERY SOLID to crash that easy .. we might be lucky and close over 0.30 lol
The selling happening now is logic and healthy . If you are Long don't panic . Will move back up in a heart beat .
0.33 is up again ! Pushing our way up to the 0.40s
BID support growing again !!! GOOO BICX
BICX New partner clinic !!
https://www.igotsober.com/intro-to-naltrexone
SUMMARY OF THE CURRENT WEEK BICX EVENTS ... can't wait for Next week :)
http://emerginggrowth.com/biocorrx-inc-otcqb-bicx-rallies-33-45-completing-equity-financing-agreement-alpine-creek-capital/
Now we are moving up ! 0.33 is up ...SOLID
imagine where the PPS will be after the 10K comes out any day now with some really decent revenues (which is expected) + announcing the final preclinical results and a confirmed FDA meeting ?
just imagine !!!!
4/5/17 - BioCorRx Announces BICX101 Preclinical Update; ASAM Attendance
Anaheim, CA (ReleaseWire) 04/05/2017 BioCorRx Inc. (OTCMKTS:BICX) (the "Company"), a developer and provider of advanced solutions in the treatment of alcohol and opioid addictions, today announced that is has received updated data from preclinical studies for BICX101, a sustained release, injectable naltrexone for the treatment of opioid abuse and alcoholism. The Company is pleased to announce that three different formulations were successful in reaching 28 days of sustained release of naltrexone. The Company also announced that it will have a booth in the exhibit hall at the American Society of Addiction Medicine (ASAM) conference in New Orleans this week. ASAM is the leading addiction medicine professional society in the U.S. representing over 4,300 physicians, clinicians and professionals with a focus on addiction and its treatment.
Brady Granier, CEO, President, and Director, stated, "We are thrilled that we have been able to hit this milestone in vivo for the first time. Thanks to the work of our team and the folks at TheraKine and Covance, we are getting closer to a final product. We still need to fine tune the formulation to maximize performance, but this data is very exciting. Not only have we reached 28 days of release, but we did it with an injection volume of only 1 ml."
Granier added, "In terms of the Pre-IND meeting request with the FDA, we are working with Innovative Science Solutions to get that done as we are eager to meet with the agency. We anticipated the request being submitted this week and we are still working to that end. It could go into next week depending on what finishing touches are needed, if any, after all regulatory experts have had a chance to review and comment on the final application. We will also be at ASAM later this week which we are very excited about as this is one of the best events in the industry. We will be meeting many key opinion leaders and educating countless addiction specialists about our BioCorRx Recovery Program and BICX101. The attendees of ASAM are all potential partners or customers for our products and programs."
About BioCorRx
BioCorRx Inc. (OTCMKTS:BICX) is an addiction treatment company offering a unique approach to the treatment of substance abuse addiction. The BioCorRx Recovery Program, a non-addictive, medication-assisted treatment (MAT) program, consists of two main components. The first component of the program consists of an outpatient implant procedure performed by a licensed physician. The implant delivers the non-addictive medicine, naltrexone, an opioid antagonist that can significantly reduce physical cravings for alcohol and opioids. The second component of the program developed by BioCorRx Inc. is a one-on-one counseling program specifically tailored for the treatment of alcoholism and other substance abuse addictions for those receiving long-term naltrexone treatment. The Company also has an R&D subsidiary, BioCorRx Pharmaceuticals, which is currently developing a new injectable naltrexone technology (BICX101) through a partnership with TheraKine Ltd. The company plans to seek FDA approval for BICX101 and/or its naltrexone implant product(s).
For more information on BICX, visitwww.BioCorRx.com.
Safe Harbor Statement
The information in this release includes forward-looking statements. These forward-looking statements generally are identified by the words "believe," "project," "estimate," "become," "plan," "will," and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties. Although the Company believes that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof.
BioCorRx Inc.
investors@BioCorRx.com
714-462-4880
Investor Relations:
Crescendo Communications, LLC
212-671-1020 x304
bicx@crescendo-ir.com
SOURCE: Uptick NewswireFor more information on this press release visit: http://www.releasewire.com/press-releases/biocorrx-announces-bicx101-preclinical-update-asam-attendance-791131.htm
April 07, 2017 09:20 ET
NSAV Announces Additional 1.5 Billion Share Reduction
CRESCO, PA--(Marketwired - Apr 7, 2017) - Net Savings Link, Inc. (OTC: NSAV) announced today that the Company has approved an additional 1.5 billion reduction of its authorized shares. This reduction follows a previously announced Company approval of a 2.5 billion authorized share reduction. This brings the total number of authorized shares that the Company has stated it will reduce to 4.0 billion or 40% of the Company's authorized shares. The management of NSAV took this action as it believed the Company's previous board had authorized an unnecessarily large amount of shares. The current NSAV management is fully committed to a policy of anti-dilution whenever feasible. The Company is presently preparing a comprehensive 8-K with regards to this and other material corporate matters.
Further, NSAV wishes to reassure all of its shareholders that no substantial dilution of its shares has taken place. The Company's transfer agent has confirmed this on numerous occasions. All NSAV shareholders are encouraged to contact the transfer agent to confirm the amount of issued and outstanding shares.
Further, although the Company's business model is growth by acquisition, the desire of NSAV is not to dilute its shareholders when making acquisitions. The Company's vision is to pay for its acquisitions out of the earnings of the companies it acquires.
NSAV also announced a reiteration of its statement that it is not planning or even considering a reverse split of its shares. The Company's president continues to standby his belief that in his 22 years in the public markets, he has never seen a reverse split benefit shareholders.
The Company also announced that its brand new corporate website is near completion and will be unveiled next week. The management of NSAV is certain that all of its shareholders will be extremely pleased when the website is launched.
James Tilton, president of NSAV, stated, "I am truly pleased that I can finally confirm the long awaited 40% reduction of the NSAV authorized shares. Once again, I can assure all of our shareholders that this action will benefit them. Protecting shareholder rights is the bedrock of the new NSAV."
Mr. Tilton went on to state, "As I Tweeted last night, I am personally extremely excited about the progress of the new NSAV corporate website. I am also honored to be involved with such a great team of developers. When the website is launched, I am certain that all NSAV shareholders will share in my excitement. In my opinion, that will finally be the day that the new era of NSAV has begun."
NSAV's vision is the establishment of a fully integrated technology company that provides turnkey technological solutions to the medical cannabis industry, as well as other areas of the medical industry. Over time, the Company plans to provide a wide range of services such as software solutions, e-commerce, advisory services, financial services, patents and trademarks and information technology.
For further information please contact NSAV at 1 (570-595-2432) or jamestilton@netsavingslinkinc.com.
The NSAV Twitter account can be accessed at https://twitter.com/NSAV_MJTechCo
The NSAV Facebook account can be accessed at https://www.facebook.com/Net-Savings-Link-Inc-768628693317257/
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, which are intended to be covered by the safe harbors created thereby. Investors are cautioned that, all forward-looking statements involve risks and uncertainties, including without limitation, the ability of Net Savings Link, Inc. to accomplish its stated plan of business. Net Savings Link, Inc. believes that the assumptions underlying the forward-looking statements contained herein are reasonable, any of the assumptions could be inaccurate, and therefore, there can be no assurance that the forward-looking statements included in this press release will prove to be accurate. In light of the significant uncertainties inherent in the forward- looking statements included herein, the inclusion of such information should not be regarded as a representation by Net Savings Link, Inc. or any other person.
Contact Information
CONTACT
NSAV
1 (570-595-2432)
jamestilton@netsavingslinkinc.com
IMO !! 0.40 + before lunch
10k out next week .. completely different PPS expected
IMO ! It will hover around the 0.30 range for rest of day . Then who knows ! 0.40-0.50 tomorrow and early next week
0.30
Blame no body but yourself when you see the 0.30+ any second and you didn't make a move yet ... LoL
goooooo BICX
They just did TODAY !
they supply the know how and the formula in different clinics all over USA ..... 0$ overhead cost / Big profit margin ..
check below news !!
Omaha's igotsober Alcohol & Opioid Recovery Center Announces Formal Opening
" Center to Offer New Medication-Assisted Treatment (MAT) with BioCorRx® "
igotsober Alcohol & Opioid Recovery Center ?
Apr 06, 2017, 08:30 ET
OMAHA, Neb., April 6, 2017 /PRNewswire/ -- igotsober Alcohol & Opioid Recovery Center today announced its formal opening. The center helps those in need throughout Omaha and the Central United States with an outpatient program offered at approximately half the cost of traditional inpatient programs. The center is conveniently located in the heart of the city at 4905 Dodge Street between N. Saddle Creek Road and N. Happy Hollow Boulevard.
There are now 23.5 million American adults addicted to drugs and/or alcohol, states the Substance Abuse and Mental Health Services Administration's (SAMHSA's) National Survey on Drug Use and Health. The new center, a trusted BioCorRx® provider, through its outpatient treatment program employs a multi-component approach and a broad recovery support structure. This includes detox assistance, the long-lasting BioCorRx® implant (using FDA-approved medicine Naltrexone which removes or largely eliminates not just the desire to use and drink, but also the associated "high"), intensive one-on-one counseling, 24/7 Sobriety Coaching, and up to 12 months of expert support led by certified Peer Recovery Support Specialists (PRSS).
The program integrates relapse prevention strategies to help patients quickly take action upon identifying emotional, mental, and physical warning signs. Family counseling sessions are also available to help loved ones better understand patterns that might unintentionally contribute to a patient's addictive behaviors. Robust programs such as this have been shown to deliver much higher success rates than conventional methods alone.
"We're thrilled to now offer Omaha and our surrounding communities what we believe to be the safest and most effective Medication-Assisted Treatment available anywhere," states Leo Allison, the center's founder. "A consultation is available now at no-cost for anyone serious about liberating themselves from the grips of drug or alcohol addiction once and for all."
For more information on the igotsober Alcohol & Opioid Recovery Center and its outpatient recovery program, call (402) 552-8890 or visit www.igotsober.com.
About the igotsober Alcohol & Opioid Recovery Center
Founded by Leo Allison, the igotsober Alcohol & Opioid Recovery Center provides a revolutionary and multi-phase outpatient treatment program fueled by Medication-Assisted Treatment (MAT), specifically the non-narcotic, 100% biodegradable implant from BioCorRx® that slowly releases the anti-craving medicine Naltrexone over a period of months. The program allows patients to integrate their therapy in real-time and in real-life thanks to a clear mind. The innovative BioCorRx® Recovery Program has provided a success rate far superior to that of conventional inpatient programs and at just one-half the cost.
Media Contact:
Leo Allison
153721@email4pr.com
4025528890
0.28 UP :))) GOT HIT ... Now 0.29 is up then 0.30 +